Madiyalakan R, Sykes T R, Dharampaul S, Sykes C J, Baum R P, Hör G, Noujaim A A
Biomira Research Inc., University of Alberta, Edmonton, Canada.
Hybridoma. 1995 Apr;14(2):199-203. doi: 10.1089/hyb.1995.14.199.
The immune status of ovarian cancer patients receiving anti-CA125 murine monoclonal antibody B43.13 was evaluated by measuring antiidiotypic antibodies (Ab2), antiantiidiotypic antibodies (Ab3), antiisotypic human antimouse antibodies (HAMA), interferon-gamma, and CA125 levels in the serum. A specific assay was developed for the determination of Ab2 antibodies using chimeric MAb B43.13. Of the 50 patients studied, 26 had elevated levels of Ab2. Eleven of these 26 patients also had high titer of antiantiidiotypic (Ab3) antibodies. Eight of the 22 patients analyzed had increased interferon-gamma levels. A tentative correlation was found between survival of these patients' antiidiotype induction.
通过检测血清中的抗独特型抗体（Ab2）、抗抗独特型抗体（Ab3）、抗同种型人抗鼠抗体（HAMA）、γ干扰素和CA125水平，评估接受抗CA125鼠单克隆抗体B43.13治疗的卵巢癌患者的免疫状态。使用嵌合单克隆抗体B43.13开发了一种用于测定Ab2抗体的特异性检测方法。在研究的50名患者中，26名患者的Ab2水平升高。这26名患者中有11名还具有高滴度的抗抗独特型（Ab3）抗体。在分析的22名患者中，有8名患者的γ干扰素水平升高。在这些患者的抗独特型诱导生存之间发现了一种初步相关性。
